193 related articles for article (PubMed ID: 36593744)
41. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
[TBL] [Abstract][Full Text] [Related]
42. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
43. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
44. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
45. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
46. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G
Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593
[TBL] [Abstract][Full Text] [Related]
47. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Khurana A; Micallef IN; LaPlant BR; Patrick O'Neill B; Habermann TM; Ansell SM; Inwards DJ; Porrata LF; Paludo J; Bisneto JCV; Johnston PB
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2217-2222. PubMed ID: 32818553
[TBL] [Abstract][Full Text] [Related]
49. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
50. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
51. Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Patil S; Spencer A; Schwarer A; Avery S; Ritchie D; Opat S; Wei A; McLean C
Leuk Lymphoma; 2009 Dec; 50(12):1964-8. PubMed ID: 19860614
[TBL] [Abstract][Full Text] [Related]
52. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
[TBL] [Abstract][Full Text] [Related]
53. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
54. [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis].
Wang Y; Liu W; Huang WY; Lyu R; Li J; Deng SH; Sui WW; Liu H; Wang TY; Yi SH; Liu HM; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):215-220. PubMed ID: 35405779
[No Abstract] [Full Text] [Related]
55. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
[TBL] [Abstract][Full Text] [Related]
56. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
57. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
58. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
59. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Schenone L; Houillier C; Tanguy ML; Choquet S; Agbetiafa K; Ghesquières H; Damaj G; Schmitt A; Bouabdallah K; Ahle G; Gressin R; Cornillon J; Houot R; Marolleau JP; Fornecker LM; Chinot O; Peyrade F; Bouabdallah R; Moluçon-Chabrot C; Gyan E; Chauchet A; Casasnovas O; Oberic L; Delwail V; Abraham J; Roland V; Waultier-Rascalou A; Willems L; Morschhauser F; Fabbro M; Ursu R; Thieblemont C; Jardin F; Tempescul A; Malaise D; Touitou V; Nichelli L; Le Garff-Tavernier M; Plessier A; Bourget P; Bonmati C; Wantz-Mézières S; Giordan Q; Dorvaux V; Charron C; Jabeur W; Hoang-Xuan K; Taillandier L; Soussain C;
Bone Marrow Transplant; 2022 Jun; 57(6):966-974. PubMed ID: 35422077
[TBL] [Abstract][Full Text] [Related]
60. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Forstpointner R; Wandt H; Freund M; Hess G; Truemper L; Diehl V; Kropff M; Kneba M; Schmitz N; Metzner B; Pfirrmann M; Unterhalt M; Hiddemann W;
Blood; 2004 Nov; 104(9):2667-74. PubMed ID: 15238420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
